Leishmania　tropica　is　a　vector-borne　parasitic　protozoa　that　is　the　leading　cause　of　leishmaniasis　throughout　the　global　tropics　and　subtropics.　L.　tropica　is　a　multidrug-resistant　parasite　with　a　diverse　set　of　serological,　biochemical,　and　genomic　features.　There　are　currently　no　particular　vaccines　available　to　combat　leishmaniasis.　The　present　study　prioritized　potential　vaccine　candidate　proteins　of　L.　tropica　using　subtractive　proteomics　and　vaccinomics　approaches.　These　vaccine　candidate　proteins　were　downstream　analyzed　to　predict　B-　and　T-cell　epitopes　based　on　high　antigenicity,　non-allergenic,　and　non-toxic　characteristics.　The　top-ranked　overlapping　MHC-I,　MHC-II,　and　linear　B-cell　epitopes　were　prioritized　for　model　vaccine　designing.　The　lead　epitopes　were　linked　together　by　suitable　linker　sequences　to　design　multi-epitope　constructs.　Immunogenic　adjuvant　sequences　were　incorporated　at　the　N-terminus　of　the　model　vaccine　constructs　to　enhance　their　immunological　potential.　Among　different　combinations　of　constructs,　four　vaccine　designs　were　selected　based　on　their　physicochemical　and　immunological　features.　The　tertiary　structure　models　of　the　designed　vaccine　constructs　were　predicted　and　verified.　The　molecular　docking　and　molecular　dynamic　(MD)　simulation　analyses　indicated　that　the　vaccine　design　V1　demonstrated　robust　and　stable　molecular　interactions　with　toll-like　receptor　4　(TLR4).　The　top-ranked　vaccine　construct　model-IV　demonstrated　significant　expressive　capability　in　the　E.　coli　expression　system　during　in-silico　restriction　cloning　analysis.　The　results　of　the　present　study　are　intriguing;　nevertheless,　experimental　bioassays　are　required　to　validate　the　efficacy　of　the　predicted　model　chimeric　vaccine.